First Time Loading...

Veru Inc
NASDAQ:VERU

Watchlist Manager
Veru Inc Logo
Veru Inc
NASDAQ:VERU
Watchlist
Price: 0.9182 USD -0.35% Market Closed
Updated: Jun 9, 2024

Intrinsic Value

VERU's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. [ Read More ]

The intrinsic value of one VERU stock under the Base Case scenario is 0.1495 USD. Compared to the current market price of 0.9182 USD, Veru Inc is Overvalued by 84%.

Key Points:
VERU Intrinsic Value
Base Case
0.1495 USD
Overvaluation 84%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Veru Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VERU stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Ask me anything about
Veru Inc

Provide an overview of the primary business activities
of Veru Inc.

What unique competitive advantages
does Veru Inc hold over its rivals?

What risks and challenges
does Veru Inc face in the near future?

Has there been any significant insider trading activity
in Veru Inc recently?

Summarize the latest earnings call
of Veru Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Veru Inc.

Provide P/S
for Veru Inc.

Provide P/E
for Veru Inc.

Provide P/OCF
for Veru Inc.

Provide P/FCFE
for Veru Inc.

Provide P/B
for Veru Inc.

Provide EV/S
for Veru Inc.

Provide EV/GP
for Veru Inc.

Provide EV/EBITDA
for Veru Inc.

Provide EV/EBIT
for Veru Inc.

Provide EV/OCF
for Veru Inc.

Provide EV/FCFF
for Veru Inc.

Provide EV/IC
for Veru Inc.

Show me price targets
for Veru Inc made by professional analysts.

What are the Revenue projections
for Veru Inc?

How accurate were the past Revenue estimates
for Veru Inc?

What are the Net Income projections
for Veru Inc?

How accurate were the past Net Income estimates
for Veru Inc?

What are the EPS projections
for Veru Inc?

How accurate were the past EPS estimates
for Veru Inc?

What are the EBIT projections
for Veru Inc?

How accurate were the past EBIT estimates
for Veru Inc?

Compare the revenue forecasts
for Veru Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Veru Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Veru Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Veru Inc compared to its peers.

Compare the P/E ratios
of Veru Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Veru Inc with its peers.

Analyze the financial leverage
of Veru Inc compared to its main competitors.

Show all profitability ratios
for Veru Inc.

Provide ROE
for Veru Inc.

Provide ROA
for Veru Inc.

Provide ROIC
for Veru Inc.

Provide ROCE
for Veru Inc.

Provide Gross Margin
for Veru Inc.

Provide Operating Margin
for Veru Inc.

Provide Net Margin
for Veru Inc.

Provide FCF Margin
for Veru Inc.

Show all solvency ratios
for Veru Inc.

Provide D/E Ratio
for Veru Inc.

Provide D/A Ratio
for Veru Inc.

Provide Interest Coverage Ratio
for Veru Inc.

Provide Altman Z-Score Ratio
for Veru Inc.

Provide Quick Ratio
for Veru Inc.

Provide Current Ratio
for Veru Inc.

Provide Cash Ratio
for Veru Inc.

What is the historical Revenue growth
over the last 5 years for Veru Inc?

What is the historical Net Income growth
over the last 5 years for Veru Inc?

What is the current Free Cash Flow
of Veru Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Veru Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Veru Inc

Current Assets 45.1m
Cash & Short-Term Investments 34.7m
Receivables 2.8m
Other Current Assets 7.6m
Non-Current Assets 26.7m
Long-Term Investments 346.4k
PP&E 5.5m
Intangibles 6.9m
Other Non-Current Assets 14m
Current Liabilities 9.6m
Accounts Payable 2.5m
Accrued Liabilities 5.6m
Other Current Liabilities 1.5m
Non-Current Liabilities 17m
Long-Term Debt 8.8m
Other Non-Current Liabilities 8.2m
Efficiency

Earnings Waterfall
Veru Inc

Revenue
13.5m USD
Cost of Revenue
-8.9m USD
Gross Profit
4.6m USD
Operating Expenses
-47.8m USD
Operating Income
-43.2m USD
Other Expenses
7.4m USD
Net Income
-35.8m USD

Free Cash Flow Analysis
Veru Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VERU Profitability Score
Profitability Due Diligence

Veru Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
11/100
Profitability
Score

Veru Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

VERU Solvency Score
Solvency Due Diligence

Veru Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
51/100
Solvency
Score

Veru Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VERU Price Targets Summary
Veru Inc

Wall Street analysts forecast VERU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VERU is 3.5088 USD with a low forecast of 1.212 USD and a high forecast of 5.25 USD.

Lowest
Price Target
1.212 USD
32% Upside
Average
Price Target
3.5088 USD
282% Upside
Highest
Price Target
5.25 USD
472% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

VERU Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

VERU Price
Veru Inc

1M 1M
-33%
6M 6M
+7%
1Y 1Y
-30%
3Y 3Y
-90%
5Y 5Y
-52%
10Y 10Y
-84%
Annual Price Range
0.9182
52w Low
0.37
52w High
1.79
Price Metrics
Average Annual Return 42.96%
Standard Deviation of Annual Returns 75.98%
Max Drawdown -98%
Shares Statistics
Market Capitalization 134.4m USD
Shares Outstanding 146 384 000
Percentage of Shares Shorted 9.68%

VERU Return Decomposition
Main factors of price return

What is price return decomposition?

VERU News

Other Videos

Last Important Events
Veru Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Veru Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Veru Inc Logo
Veru Inc

Country

United States of America

Industry

Consumer products

Market Cap

134.4m USD

Dividend Yield

0%

Description

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. The company is headquartered in Miami, Florida and currently employs 252 full-time employees. The firm is focused on developing medicines for the management of breast and prostate cancers. The firm's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. The company has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Contact

FLORIDA
Miami
2916 N. Miami Avenue, Suite 1000
+13125959123.0
https://verupharma.com/

IPO

1990-07-19

Employees

252

Officers

Chairman, President & CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Vice Chairman & Chief Corporate Officer
Dr. Harry Fisch F.A.C.S., M.D.
CFO & Chief Administrative Officer
Ms. Michele Greco
Chief Scientific Officer
Dr. K. Gary Barnette Ph.D.
Executive Director of Investor Relations & Corporate Communications
Mr. Samuel Fisch
Executive VP, General Counsel & Corporate Strategy and Secretary
Mr. Michael J. Purvis
Show More
Executive Vice President of Corporate Development
Mr. Kevin J. Gilbert CPA, J.D.
Executive Vice President of FC2 Global Operations
Mr. Martin Tayler
Executive VP & Deputy General Counsel
Mr. Philip R. Greenberg J.D.
Executive Vice President of Global Clinical Operations
Dr. Domingo Rodriguez M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one VERU stock?

The intrinsic value of one VERU stock under the Base Case scenario is 0.1495 USD.

Is VERU stock undervalued or overvalued?

Compared to the current market price of 0.9182 USD, Veru Inc is Overvalued by 84%.